HAG
HighPoint Advisor Group’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $361K | Buy |
2,871
+59
| +2% | +$7.42K | 0.02% | 460 |
|
|
2025
Q1 | $302K | Buy |
2,812
+366
| +15% | +$39.3K | 0.02% | 487 |
|
|
2024
Q4 | $286K | Buy |
2,446
+96
| +4% | +$11.2K | 0.02% | 524 |
|
|
2024
Q3 | $287K | Buy |
2,350
+425
| +22% | +$51.9K | 0.02% | 500 |
|
|
2024
Q2 | $272K | Sell |
1,925
-633
| -25% | -$89.4K | 0.02% | 501 |
|
|
2024
Q1 | $348K | Buy |
2,558
+48
| +2% | +$6.53K | 0.02% | 425 |
|
|
2023
Q4 | $352K | Buy |
+2,510
| New | +$352K | 0.03% | 431 |
|
|
2022
Q2 | $207K | Buy |
+2,178
| New | +$207K | 0.02% | 487 |
|